U1 snrnp-dependent suppression of polyadenylation: Physiological role and therapeutic opportunities in cancer

International Journal of Cell Biology

Volumn , Issue , 2013, Pages

  Spraggon, Lee ^a   Cartegni, Luca ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA PRECURSOR; SMALL NUCLEAR RIBONUCLEOPROTEIN;

3' UNTRANSLATED REGION; CANCER THERAPY; DEREGULATION; GENETIC ASSOCIATION; NEOPLASM; POLYADENYLATION; PRIORITY JOURNAL; REVIEW; RNA PROCESSING; SPLICEOSOME;

EUKARYOTA;

EID: 84888880619     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2013/846510     Document Type: Review

References (72)

1. Kalsotra A., Cooper T. A., Functional consequences of developmentally regulated alternative splicing. Nature Reviews Genetics 2011 12 10 715 729 2-s2.0-80053027909 10.1038/nrg3052
2. Kornblihtt A. R., Schor I. E., Allo M., Dujardin G., Petrillo E., Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nature Reviews Molecular Cell Biology 2013 14 153 165
3. Nilsen T. W., Graveley B. R., Expansion of the eukaryotic proteome by alternative splicing. Nature 2010 463 7280 457 463 2-s2.0-75849145292 10.1038/nature08909
4. Cartegni L., Chew S. L., Krainer A. R., Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nature Reviews Genetics 2002 3 4 285 298 2-s2.0-0036207384 10.1038/nrg775 (Pubitemid 34279797)
5. Singh R. K., Cooper T. A., Pre-mRNA splicing in disease and therapeutics. Trends in Molecular Medicine 2012 18 8 472 482 10.1016/j.molmed.2012.06.006
6. Ghigna C., Valacca C., Biamonti G., Alternative splicing and tumor progression. Current Genomics 2008 9 8 556 570 2-s2.0-66049085709 10.2174/138920208786847971
7. Elkon R., Ugalde A. P., Agami R., Alternative cleavage and polyadenylation: extent, regulation and function. Nature Reviews Genetics 2013 14 496 506 10.1038/nrg3482
8. Wahl M. C., Will C. L., Lührmann R., The spliceosome: design principles of a dynamic RNP machine. Cell 2009 136 4 701 718 2-s2.0-60349104299 10.1016/j.cell.2009.02.009
9. Roca X., Krainer A. R., Eperon I. C., Pick one, but be quick: 5' splice sites and the problems of too many choices. Genes & Development 2013 27 129 144 10.1101/gad.209759.112
10. Beserga S. J., Steitz J. A., Gesteland R. F., Atkins J. F., The diverse world of small ribonucleoproteins. The RNA World. Cold Spring Harbor 1993 CSHL Press 359 381
11. Reddy R., Busch H., Birnstiel M., RNA sequences, structure, and modifications. Structure and Function of Major and Minor Small Nuclear Ribonucleoprotein Particles 1988 New York, NY, USA Springer 1 37
12. Wassarman K. M., Steitz J. A., Association with terminal exons in pre-mRNAs: a new role for the U1 snRNP? Genes and Development 1993 7 4 647 659 2-s2.0-0027153540 (Pubitemid 23125264)
13. Boelens W. C., Jansen E. J. R., Van Venrooij W. J., Stripecke R., Mattal I. W., Gunderson S. I., The human U1 snRNP-specific U1A protein inhibits polyadenylation of its own pre-mRNA. Cell 1993 72 6 881 892 2-s2.0-0027471377 10.1016/0092-8674(93)90577-D (Pubitemid 23110230)
14. Proudfoot N. J., Ending the message: poly(A) signals then and now. Genes and Development 2011 25 17 1770 1782 2-s2.0-80052447253 10.1101/gad.17268411
15. Tian B., Hu J., Zhang H., Lutz C. S., A large-scale analysis of mRNA polyadenylation of human and mouse genes. Nucleic Acids Research 2005 33 1 201 212 2-s2.0-13744254695 10.1093/nar/gki158 (Pubitemid 40276942)
16. Ozsolak F., Kapranov P., Foissac S., Kim S. W., Fishilevich E., Monaghan A. P., John B., Milos P. M., Comprehensive polyadenylation site maps in yeast and human reveal pervasive alternative polyadenylation. Cell 2010 143 6 1018 1029 2-s2.0-78649910014 10.1016/j.cell.2010.11.020
17. Tian B., Pan Z., Ju Y. L., Widespread mRNA polyadenylation events in introns indicate dynamic interplay between polyadenylation and splicing. Genome Research 2007 17 2 156 165 2-s2.0-33846870354 10.1101/gr.5532707 (Pubitemid 46220760)
18. Tian B., Manley J. L., Alternative cleavage and polyadenylation: the long and short of it. Trends in Biochemical Sciences 2013 38 6 312 320 10.1016/j.tibs.2013.03.005
19. Vorlová S., Rocco G., LeFave C. V., Jodelka F. M., Hess K., Hastings M. L., Henke E., Cartegni L., Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polya activation. Molecular Cell 2011 43 6 927 939 2-s2.0-80052999677 10.1016/j.molcel.2011.08.009
20. Spies N., Nielsen C. B., Padgett R. A., Burge C. B., Biased chromatin signatures around polyadenylation sites and exons. Molecular Cell 2009 36 2 245 254 2-s2.0-70350013550 10.1016/j.molcel.2009.10.008
21. Morris A. R., Bos A., Diosdado B., Rooijers K., Elkon R., Alternative cleavage and polyadenylation during colorectal cancer development. Clinical Cancer Research 2012 18 5256 5266 10.1158/1078-0432.CCR-12-0543
22. Fu Y., Sun Y., Li Y., Li J., Rao X., Chen C., Xu A., Differential genome-wide profiling of tandem 3' UTRs among human breast cancer and normal cells by high-throughput sequencing. Genome Research 2011 21 5 741 747 2-s2.0-79955554179 10.1101/gr.115295.110
23. Mayr C., Bartel D. P., Widespread shortening of 3' UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 2009 138 4 673 684 2-s2.0-68749113985 10.1016/j.cell.2009.06.016
24. Sandberg R., Neilson J. R., Sarma A., Sharp P. A., Burge C. B., Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. Science 2008 320 5883 1643 1647 2-s2.0-46249092601 10.1126/science.1155390 (Pubitemid 351931255)
25. Knudsen K. E., The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Division 2006 1, article 15 2-s2.0-33845394286 10.1186/1747-1028-1- 15 (Pubitemid 46731039)
26. Albuquerque R. J. C., Hayashi T., Cho W. G., Kleinman M. E., Dridi S., Takeda A., Baffi J. Z., Yamada K., Kaneko H., Green M. G., Chappell J., Wilting J., Weich H. A., Yamagami S., Amano S., Mizuki N., Alexander J. S., Peterson M. L., Brekken R. A., Hirashima M., Capoor S., Usui T., Ambati B. K., Ambati J., Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nature Medicine 2009 15 9 1023 1030 2-s2.0-69949160832 10.1038/nm.2018
27. Becker J., Pavlakovic H., Ludewig F., Wilting F., Weich H. A., Albuquerque R., Ambati J., Wilting J., Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. Clinical Cancer Research 2010 16 5 1431 1441 2-s2.0-77649129758 10.1158/1078-0432.CCR-09-1936
28. Bava F. A., Eliscovich C., Ferreira P. G., Minana B., Ben-Dov C., CPEB1 coordinates alternative 3'-UTR formation with translational regulation. Nature 2013 495 7439 121 125 10.1038/nature11901
29. Danckwardt S., Kaufmann I., Gentzel M., Foerstner K. U., Gantzert A.-S., Gehring N. H., Neu-Yilik G., Bork P., Keller W., Wilm M., Hentze M. W., Kulozik A. E., Splicing factors stimulate polyadenylation via USEs at non-canonical 3' end formation signals. EMBO Journal 2007 26 11 2658 2669 2-s2.0-34250012298 10.1038/sj.emboj.7601699 (Pubitemid 46884270)
30. Moreira A., Takagaki Y., Brackenridge S., Wollerton M., Manley J. L., Proudfoot N. J., The upstream sequence element of the C2 complement poly(A) signal activates mRNA 3' end formation by two distinct mechanisms. Genes and Development 1998 12 16 2522 2534 2-s2.0-0032529163 (Pubitemid 28406955)
31. Castelo-Branco P., Furger A., Wollerton M., Smith C., Moreira A., Proudfoot N., Erratum: polypyrimidine tract binding protein modulates efficiency of polyadenylation. Molecular and Cellular Biology 2004 24 15 4174 4183 2-s2.0-3242722144 10.1128/MCB.24.15.6889.2004 (Pubitemid 38944367)
32. Moore C. L., Sharp P. A., Site-specific polyadenylation in a cell-free reaction. Cell 1984 36 3 581 591 2-s2.0-0021274914 (Pubitemid 14126196)
33. Moore C. L., Sharp P. A., Accurate cleavage and polyadenylation of exogenous RNA substrate. Cell 1985 41 3 845 855 2-s2.0-0022098633
34. Hashimoto C., Steitz J. A., A small nuclear ribonucleoprotein associates with the AAUAAA polyadenylation signal in vitro. Cell 1986 45 4 581 591 2-s2.0-0023055543
35. Van Gelder C. W. G., Gunderson S. I., Jansen E. J. R., Boelens W. C., Polycarpou-Schwarz M., Mattaj I. W., Van Venrooij W. J., A complex secondary structure in U1A pre-mRNA that binds two molecules of U1A protein is required for regulation of polyadenylation. EMBO Journal 1993 12 13 5191 5200 2-s2.0-0027453554 (Pubitemid 23358509)
36. Gunderson S. I., Beyer K., Martin G., Keller W., Boelens W. C., Mattaj I. W., The human U1A snRNP protein regulates polyadenylation via a direct interaction with poly(A) polymerase. Cell 1994 76 3 531 541 2-s2.0-0028173689 10.1016/0092-8674(94)90116-3
37. Phillips C., Jung S., Gunderson S. I., Regulation of nuclear poly(A) addition controls the expression of immunoglobulin M secretory mRNA. EMBO Journal 2001 20 22 6443 6452 2-s2.0-0035890325 10.1093/emboj/20.22.6443 (Pubitemid 33078717)
38. Phillips C., Pachikara N., Gunderson S. I., U1A inhibits cleavage at the immunoglobulin M heavy-chain secretory poly(A) site by binding between the two downstream GU-rich regions. Molecular and Cellular Biology 2004 24 14 6162 6171 2-s2.0-3042789288 10.1128/MCB.24.14.6162-6171.2004 (Pubitemid 38891119)
39. Ma J., Gunderson S. I., Phillips C., Non-snRNP U1A levels decrease during mammalian B-cell differentiation and release the IgM secretory poly(A) site from repression. RNA 2006 12 1 122 132 2-s2.0-29844454986 10.1261/rna.2159506 (Pubitemid 43037460)
40. Furth P. A., Choe W.-T., Rex J. H., Byrne J. C., Baker C. C., Sequences homologous to 5' splice sites are required for the inhibitory activity of papillomavirus late 3' untranslated regions. Molecular and Cellular Biology 1994 14 8 5278 5289 2-s2.0-0027982009
41. Gunderson S. I., Polycarpou-Schwarz M., Mattaj I. W., U1 snRNP inhibits pre-mRNA polyadenylation through a direct interaction between U1 70K and poly(A) polymerase. Molecular Cell 1998 1 2 255 264 2-s2.0-0031610367 (Pubitemid 128378666)
42. Ashe M. P., Furger A., Proudfoot N. J., Stem-loop 1 of the U1 snRNP plays a critical role in the suppression of HIV-1 polyadenylation. RNA 2000 6 2 170 177 2-s2.0-0033952258 10.1017/S1355838200991957 (Pubitemid 30091588)
43. Ashe M. P., Pearson L. H., Proudfoot N. J., The HIV-1 5' LTR poly (A) site is inactivated by U1 snRNP interaction with the downstream major splice donor site. EMBO Journal 1997 16 18 5752 5763 2-s2.0-0030821340 10.1093/emboj/16.18.5752 (Pubitemid 27399866)
44. Beckley S. A., Liu P., Stover M. L., Gunderson S. I., Lichtler A. C., Rowe D. W., Reduction of target gene expression by a modified U1 snRNA. Molecular and Cellular Biology 2001 21 8 2815 2825 2-s2.0-0035083167 10.1128/MCB.21.8.2815-2825.2001 (Pubitemid 32244925)
45. Fortes P., Cuevas Y., Guan F., Liu P., Pentlicky S., Jung S. P., Martínez-Chantar M. L., Prieto J., Rowe D., Gunderson S. I., Inhibiting expression of specific genes in mammalian cells with 5′ end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-MRNA. Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8264 8269 2-s2.0-0038492463 10.1073/pnas.1332669100 (Pubitemid 36842533)
46. Abad X., Vera M., Jung S. P., Oswald E., Romero I., Amin V., Fortes P., Gunderson S. J., Requirements for gene silencing mediated by U1 snRNA binding to a target sequence. Nucleic Acids Research 2008 36 7 2338 2352 2-s2.0-42449160202 10.1093/nar/gkn068 (Pubitemid 351567007)
47. Goraczniak R., Behlke M. A., Gunderson S. I., Gene silencing by synthetic U1 Adaptors. Nature Biotechnology 2009 27 3 257 263 2-s2.0-62149127652 10.1038/nbt.1525
48. Kaida D., Berg M. G., Younis I., Kasim M., Singh L. N., Wan L., Dreyfuss G., U1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation. Nature 2010 468 7324 664 668 2-s2.0-78649847070 10.1038/nature09479
49. Almada A. E., Wu X., Kriz A. J., Burge C. B., Sharp P. A., Promoter directionality is controlled by U1 snRNP and polyadenylation signals. Nature 2013 2013 10.1038/nature12349
50. Berg M. G., Singh L. N., Younis I., Liu Q., Pinto A. M., U1 snRNP determines mRNA length and regulates isoform expression. Cell 2012 150 53 64 10.1016/j.cell.2012.05.029
51. Roca X., Krainer A. R., Recognition of atypical 5' splice sites by shifted base-pairing to U1 snRNA. Nature Structural and Molecular Biology 2009 16 2 176 182 2-s2.0-59649083526 10.1038/nsmb.1546
52. Zhang X. H.-F., Heller K. A., Hefter I., Leslie C. S., Chasin L. A., Sequence information for the splicing of human pre-mRNA identified by support vector machine classification. Genome Research 2003 13 12 2637 2650 2-s2.0-0346121460 10.1101/gr.1679003 (Pubitemid 37541152)
53. Lejeune F., Maquat L. E., Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. Current Opinion in Cell Biology 2005 17 3 309 315 2-s2.0-19344366251 10.1016/j.ceb.2005.03.002 (Pubitemid 40719922)
54. Graille M., Seraphin B., Surveillance pathways rescuing eukaryotic ribosomes lost in translation. Nature Reviews Molecular Cell Biology 2012 13 727 735 10.1038/nrm3457
55. Spraggon L., Cartegni L., Antisense modulation of RNA processing as a therapeutic approach in cancer therapy. Drug Discovery Today 2013 10.1016/j.ddstr.2013.06.002
56. Goraczniak R., Wall B. A., Behlke M. A., Lennox K. A., Ho E. S., U1 adaptor oligonucleotides targeting BCL2 and GRM1 suppress growth of human melanoma xenografts in vivo. Molecular Therapy 2013 2 e92 10.1038/mtna.2013.24
57. Teh J. L. F., Chen S., Glutamatergic signaling in cellular transformation. Pigment Cell and Melanoma Research 2012 25 331 342 2-s2.0-84857136604 10.1111/j.1755-148X.2012.00983.x
58. Prickett T. D., Samuels Y., Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clinical Cancer Research 2012 18 4240 4246 10.1158/1078-0432.CCR-11-1217
59. Youle R. J., Strasser A., The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology 2008 9 1 47 59 2-s2.0-37549048249 10.1038/nrm2308
60. Ruoslahti E., RGD and other recognition sequences for integrins. Annual Review of Cell and Developmental Biology 1996 12 697 715 2-s2.0-0029775681 10.1146/annurev.cellbio.12.1.697 (Pubitemid 26422728)
61. Weirauch U., Grünweller A., Cuellar L., Hartmann R. K., Aigner A., U1 adaptors for the therapeutic knockdown of the oncogene pim-1 kinase in glioblastoma. Nucleic Acid Therapeutics 2013 23 4 264 272 10.1089/nat.2012.0407
62. Zhang T., Zhang X., Ding K., Yang K., Zhang Z., Xu Y., PIM-1 gene RNA interference induces growth inhibition and apoptosis of prostate cancer cells and suppresses tumor progression in vivo. Journal of Surgical Oncology 2010 101 6 513 519 2-s2.0-77950803910 10.1002/jso.21524
63. Vickers T. A., Sabripour M., Crooke S. T., U1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP. Nucleic Acids Research 2011 39 10 e71 2-s2.0-79961189939 10.1093/nar/gkr150
64. Havens M. A., Duelli D. M., Hastings M. L., Targeting RNA splicing for disease therapy. RNA 2013 4 3 247 266 10.1002/wrna.1158
65. Zammarchi F., De Stanchina E., Bournazou E., Supakorndej T., Martires K., Riedel E., Corben A. D., Bromberg J. F., Cartegni L., Antitumorigenic potential of STAT3 alternative splicing modulation. Proceedings of the National Academy of Sciences of the United States of America 2011 108 43 17779 17784 2-s2.0-80055072546 10.1073/pnas.1108482108
66. Gschwind A., Fischer O. M., Ullrich A., The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Reviews Cancer 2004 4 5 361 370 2-s2.0-2342591455 (Pubitemid 38579482)
67. Lemmon M. A., Schlessinger J., Cell signaling by receptor tyrosine kinases. Cell 2010 141 7 1117 1134 2-s2.0-77953896432 10.1016/j.cell.2010.06.011
68. Yarden Y., Pines G., The ERBB network: at last, cancer therapy meets systems biology. Nature Reviews Cancer 2012 12 553 563
69. Tiran Z., Oren A., Hermesh C., Rotman G., Levine Z., Amitai H., Handelsman T., Beiman M., Chen A., Landesman-Milo D., Dassa L., Peres Y., Koifman C., Glezer S., Vidal-Finkelstein R., Bahat K., Pergam T., Israel C., Horev J., Tsarfaty I., Ayalon-Soffer M., A novel recombinant soluble splice variant of met is a potent antagonist of the hepatocyte growth factor/scatter factor-met pathway. Clinical Cancer Research 2008 14 14 4612 4621 2-s2.0-51649111766 10.1158/1078-0432.CCR-08-0108
70. Ciombor K. K., Berlin J., Chan E., Aflibercept. Clinical Cancer Research 2013 19 1920 1925 10.1158/1078-0432.CCR-12-2911
71. Claesson-Welsh L., Welsh M., VEGFA and tumour angiogenesis. Journal of Internal Medicine 2013 273 2 114 127 10.1111/joim.12019
72. Owen L. A., Uehara H., Cahoon J., Huang W., Simonis J., Ambati B. K., Morpholino-mediated increase in soluble flt-1 expression results in decreased ocular and tumor neovascularization. PLoS ONE 2012 7 3 2-s2.0-84858220005 10.1371/journal.pone.0033576 e33576